{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-115681","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2021-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.676495+00:00","generated_at":"2026-06-29T03:32:23.749755+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Theravance cuts 75% of staff; ampreloxetine Phase 3 misses primary endpoint","bullets":["Headcount reduction of ~75% (~270 positions); most complete Nov 2021, remainder Feb 2022.","Estimated $165M annualized operating expense savings in 2022; expects cash flow positive from 2H 2022.","Ampreloxetine Phase 3 study (0169) failed to meet primary endpoint; no safety concerns.","EVP & General Counsel Shafer resigns; SVP Sabesan leaves Nov 30; two directors (Whitesides, Gunderson) resign."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-115681","json":"https://secwatch.observer/filing/0001104659-21-115681.json","markdown":"https://secwatch.observer/filing/0001104659-21-115681.md","text":"https://secwatch.observer/filing/0001104659-21-115681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/tm2127424d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:32:23.749755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"230c2ed410","claim":"Vijay Sabesan departed as Senior Vice President, Technical Operations at Theravance Biopharma, Inc..","evidence_excerpt":"Vijay Sabesan, Senior Vice President, Technical Operations, a “named executive officer” from 2021, will leave the Company on November 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Senior Vice President, Technical Operations"}],"fact_type":"executive_change"},{"claim_id":"3387f04585","claim":"Robert V. Gunderson, Jr. resigned as Director at Theravance Biopharma, Inc..","evidence_excerpt":"Robert V. Gunderson, Jr. notified the Company of his resignation as a Director of the Company effective September 11, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4a6e8b757e","claim":"Braford J. Shafer resigned as Executive Vice President and General Counsel at Theravance Biopharma, Inc..","evidence_excerpt":"On September 13, 2021, Braford J. Shafer, a “named executive officer” from 2021, notified the Company of his resignation as its Executive Vice President and General Counsel effective on September 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and General Counsel"}],"fact_type":"executive_change"},{"claim_id":"b2797c7501","claim":"George M. Whitesides resigned as Director at Theravance Biopharma, Inc..","evidence_excerpt":"George M. Whitesides notified the Company of his resignation as a Director of the Company effective September 14, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}